News

Publication of a Shareholders Letter – Offentliggørelse af nyhedsbrev til aktionærerne

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of a Shareholders Letter (1). This Shareholders Letter updates on major achievements of the first half of 2015 and on the company’s short and middle term catalysts. (1)    The Shareholders Letter is available on the website at: www.onxeo.com…read more →

Onxeo Reports First Half 2015 Business Update and Consolidated Accounts – Onxeo informerer om sine forretningsmæssige tiltag og resultatet for 1. halvår 2015

Livatag® Phase III trial in HCC: 50% of patients randomized Scientific recognition of Validive® and Beleodaq® preclinical and clinical data at ASCO Annual  Meeting and MASCC/ISOO International Symposium Sound financial position with €42.9 million cash  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today reported its consolidated half-year accounts as…read more →

Update on ReLive, Livatag® international phase III clinical trial in HCC – 50% patients randomized – Opdatering om ReLive, det internationale kliniske fase III-studie med Livatag® til behandling af leverkræft 50% patienter randomiseret

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, updates on the clinical development status of ReLive , the Livatag® phase III trial  in the treatment of hepatocellular carcinoma. Livatag®, a new therapeutic approach for hepatocellular carcinoma Livatag® is based on the innovative « Transdrug ™ » technology  designed to formulate a chemotherapy (doxorubicin)…read more →

Meetings with the financial community during the 2nd semester of 2015 – Møder med finansverdenen i 2. halvår 2015

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces its meetings with the investors and shareholders during the second semester 2015. September 16, 2015 11:30am: – Analyst and Investor Meeting 5:30pm: Audio/web conference September 22, 2015 InvestorDagen Radisson Blu Scandinavia Hotel – Copenhagen, Denmark October 7 & 8, 2015 European…read more →

Validive® at the MASCC/ISOO International Symposium: Oral presentation of Phase II trial results and meeting with its International Advisory Board – Data om Validive® på MASCC/ISOO International Symposium: Mundtlig præsentation af resultater fra fase II-studiet og møde med det internationale ekspertudvalg

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, has presented Validive® (clonidine Lauriad®) Phase II clinical trial results at the MASCC/ISOO International Symposium which took place in Copenhagen from June 25 to June 27, 2015 and on this occasion, held a meeting of its Advisory Board to discuss  design of…read more →

Beleodaq® (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology (JCO) – Resultater fra det pivotale BELIEF-studie med Beleodaq® (belinostat) publiceret i Journal of Clinical Oncology (JCO)

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced the publication of results from the pivotal BELIEF (PXD101-CLN-19) study which was selected as a Rapid Communication in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology.  The JCO is peer-reviewed and is one…read more →

Onxeo consolidates its industrial property with a US patent protecting Validive® until 2029 – Onxeo styrker sine immaterielle rettigheder med et amerikansk patent til beskyttelse af Validive® frem til 2029

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced the allowance by the US Patent and Trademark  Office (USPTO) of a patent covering its product Validive® until September 2029. Validive® is based on Onxeo’s mucoadhesive technology Lauriad® and has obtained positive Phase II results last year in the prevention…read more →

Onxeo meets US Investors during “French Life Sciences Days” event in New York on June 17 & 18, 2015 – Onxeo mødes med amerikanske investorer under “French Life Sciences Days” i New York den 17. og 18. juni 2015

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced today its participation in the “French Life Sciences Days” to be held in New York on June 17 & 18, 2015. Initiated by France Biotech,  the event “French Life Sciences Days” aims to bring together French Life Sciences companies listed on…read more →

Onxeo Announces Preclinical & Clinical Data from Three Studies Supporting the Potential For Belinostat in Multiple Orphan Oncology Indications – Onxeo offentliggør prækliniske og kliniske data fra tre studier, som understøtter potentialet for belinostat i en række sjældne kræftindikationer

Findings provide key validation; help identify target indications for optimal development Data demonstrating safety and efficacy to be presented at ASCO Annual Meeting 2015 on Sunday, May 31 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced preclinical & clinical data from three studies supporting of the potential of…read more →

Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients – Onxeo offentliggør endelige data fra gennemført fase II-studie med Validive® til forebyggelse af svær oral mucositis hos patienter med hoved-halskræft

Data confirm Validive® efficacy and safety; Provide basis for planned Phase 3 Trial Full results to be presented at ASCO Annual Meeting 2015 on Saturday, May 30 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced the final data from its global Phase II clinical trial of Validive® (clonidine…read more →

Onxeo’s Combined General Meeting of Shareholders – Forløb af Onxeos ordinære generalforsamling

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the General Meeting, held at the company’s headquarters in Paris, France on May 20, 2015, adopted all of the resolutions recommended by the Board of Directors. Please be advised that the voting results of the Combined General Meeting are…read more →

Publication of a Letter to Shareholders – May 2015 – Offentliggørelse af nyhedsbrev til aktionærerne – maj 2015

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of the Letter to Shareholders – May 2015. Letter to Shareholders, May 2015 150512EN_PR Letter to Shareholders, May 2015 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), et innovativt selskab med speciale i udvikling af lægemidler til behandling af…read more →

Oral presentation of Phase II trial results of Validive® at the MASCC/ISOO International Symposium – Mundtlig præsentation af resultater fra fase II-studiet med Validive® på MASCC/ISOO International Symposium

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that Validive® (clonidine Lauriad®) phase II clinical trial results have been accepted for an oral presentation at the MASCC/ISOO International Symposium taking place in Copenhagen from June 25 to June 27, 2015. The MASCC/ISOO Annual meeting is dedicated to supportive…read more →

Belinostat abstracts for American Association for Cancer Research 2015 – Abstracts om belinostat på 2014 årsmødet i American Association for Cancer Research

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that preclinical and clinical data on belinostat will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting (April 18-22, 2015) in Philadelphia (Pennsylvania), USA. Preclinical and clinical abstracts involving belinostat will be featured at the AACR…read more →